However, unlike the gain-of-function mutations of the above RTKs frequently seen in lung cancers,[21–25] we have not encountered any such mutations of the PKC isoforms investigated in the cohort of MPM tumor samples (data not shown). This evidence concerns the gene PRRT2 and lung carcinoma.